[go: up one dir, main page]

CL2019003015A1 - Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. - Google Patents

Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Info

Publication number
CL2019003015A1
CL2019003015A1 CL2019003015A CL2019003015A CL2019003015A1 CL 2019003015 A1 CL2019003015 A1 CL 2019003015A1 CL 2019003015 A CL2019003015 A CL 2019003015A CL 2019003015 A CL2019003015 A CL 2019003015A CL 2019003015 A1 CL2019003015 A1 CL 2019003015A1
Authority
CL
Chile
Prior art keywords
ahr
inhibitors
aryl hydrocarbon
hydrocarbon receptor
indole aryl
Prior art date
Application number
CL2019003015A
Other languages
English (en)
Inventor
Alfredo C Castro
Catherine Anne Evans
Original Assignee
Kyn Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyn Therapeutics filed Critical Kyn Therapeutics
Publication of CL2019003015A1 publication Critical patent/CL2019003015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS ÚTILES COMO INHIBIDORES DE AHR, COMPOSICIONES DE LOS MISMOS Y MÉTODOS PARA USAR LOS MISMOS.
CL2019003015A 2017-04-21 2019-10-21 Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. CL2019003015A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488476P 2017-04-21 2017-04-21
US201762592542P 2017-11-30 2017-11-30
US201862658454P 2018-04-16 2018-04-16

Publications (1)

Publication Number Publication Date
CL2019003015A1 true CL2019003015A1 (es) 2020-03-27

Family

ID=63856153

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003015A CL2019003015A1 (es) 2017-04-21 2019-10-21 Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Country Status (15)

Country Link
US (5) US10570138B2 (es)
EP (1) EP3612030B1 (es)
JP (2) JP7232244B2 (es)
KR (1) KR102668371B1 (es)
CN (1) CN110831600B (es)
AU (1) AU2018256459B2 (es)
CA (1) CA3059939A1 (es)
CL (1) CL2019003015A1 (es)
CO (1) CO2019011584A2 (es)
IL (1) IL270025B2 (es)
MX (1) MX2019012431A (es)
SG (1) SG11201909710XA (es)
TW (1) TWI778050B (es)
WO (1) WO2018195397A2 (es)
ZA (1) ZA201906822B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981911B2 (en) 2016-12-16 2021-04-20 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11059823B2 (en) 2016-12-16 2021-07-13 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11066406B2 (en) 2018-06-15 2021-07-20 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908624SA (en) * 2017-04-12 2019-10-30 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and uses thereof
EP3612030B1 (en) 2017-04-21 2025-12-24 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
FR3066761B1 (fr) * 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
AU2018319016B2 (en) 2017-08-17 2023-08-31 Ikena Oncology, Inc. AHR inhibitors and uses thereof
WO2019156989A1 (en) * 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
EP3749669B3 (en) 2018-02-06 2024-09-04 Ideaya Biosciences, Inc. Ahr modulators
EP3847176A1 (en) * 2018-09-07 2021-07-14 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
AU2019360204A1 (en) * 2018-10-16 2021-06-03 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
CA3115825A1 (en) * 2018-10-17 2020-04-23 Magenta Therapeutics, Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists
JP2022511457A (ja) * 2018-11-30 2022-01-31 セルラリティ インク． 造血幹細胞および前駆細胞の活性化に使用するための芳香族化合物
KR20210111762A (ko) * 2018-11-30 2021-09-13 셀룰래리티 인코포레이티드 신규 방향족 화합물을 사용한 자연 살해 세포 및 ilc3 세포의 증식
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
WO2020176772A1 (en) 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
EP4003337A4 (en) * 2019-07-30 2023-06-28 Oregon State University Aryl hydrocarbon receptor activators
MX2022006086A (es) * 2019-11-22 2022-09-07 Senda Biosciences Inc Derivados de piridopirimidinona como antagonistas de ahr.
KR20220106126A (ko) * 2019-11-26 2022-07-28 에프. 호프만-라 로슈 아게 자가면역 질환의 치료를 위한 1,8-나프티리딘-2-온 화합물
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
JP2023503167A (ja) * 2019-11-26 2023-01-26 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
US20230039711A1 (en) 2020-01-10 2023-02-09 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
EP4110778A1 (en) 2020-02-26 2023-01-04 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
WO2021194326A1 (en) * 2020-03-27 2021-09-30 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
US20240350492A1 (en) 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss
WO2022029063A1 (en) * 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
AU2021369590A1 (en) * 2020-10-28 2023-06-22 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
CN114644627B (zh) * 2020-12-18 2024-06-11 山东轩竹医药科技有限公司 AhR抑制剂及其用途
CN112656789A (zh) * 2020-12-31 2021-04-16 中国科学院生态环境研究中心 Ficz在抑制肿瘤细胞迁移中的应用
CN114805361B (zh) * 2021-01-17 2024-02-20 上海凌达生物医药有限公司 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN115093400B (zh) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN115925684B (zh) * 2021-12-03 2025-02-28 徐诺药业(南京)有限公司 一种嘧啶类衍生物及其制备方法和应用
WO2023135057A1 (en) 2022-01-11 2023-07-20 Deutsches Krebsforschungszentrum Bicyclic triazine derivatives for the treatment of cancer
IL315733A (en) 2022-04-08 2024-11-01 SHY Therapeutics LLC Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases
CN117624168A (zh) * 2022-08-19 2024-03-01 德明药泰生物技术（深圳）有限公司 稠环杂环类化合物及其制备方法和应用
CN115850329A (zh) * 2022-09-16 2023-03-28 东莞市均成高新材料有限公司 环三联芳膦、它们的制备方法及用途
KR20250073623A (ko) 2022-10-03 2025-05-27 재규어 테라퓨틱스 피티이 리미티드 AhR 신호전달의 조절에 유용한 화합물
CN115804776A (zh) * 2022-12-16 2023-03-17 国纳之星(上海)纳米科技发展有限公司 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用
CN116482278B (zh) * 2023-05-06 2024-02-09 广州清瑞生物科技有限责任公司 一种用于检测阿昔洛韦的对照品的制备方法
TW202510855A (zh) * 2023-08-18 2025-03-16 美商英塞特公司 作為ｍｒｇｐｒｘ２拮抗劑之雙環雜環化合物
EP4512427A1 (en) 2023-08-25 2025-02-26 Mablink Bioscience Antibody-drug conjugates based on molecular glue degraders and uses thereof
EP4512806A1 (en) 2023-08-25 2025-02-26 Mablink Bioscience Molecular glue degraders and uses thereof
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
WO2025114771A1 (en) 2023-11-29 2025-06-05 Latvian Institute Of Organic Synthesis A new class of aryl hydrocarbon receptor antagonists and their optimisation
WO2025254418A1 (ko) * 2024-06-03 2025-12-11 동아에스티 주식회사 아미노피리미딘 유도체의 결정다형 및 이의 제조방법

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
EP0915880B1 (en) * 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
US5962473A (en) 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CZ20031776A3 (cs) * 2000-12-19 2003-09-17 Merck Patent Gmbh Farmaceutický prostředek obsahující deriváty pyrazolo [4,3-d]-pyrimidinu a antitrombotika, vápníkové antagonisty, prostaglandiny nebo deriváty prostaglandinu (2)
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
CA2497444C (en) * 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026867A2 (en) * 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
CA2520323C (en) 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
KR20070118068A (ko) 2004-11-23 2007-12-13 레디 유에스 테라퓨틱스 인코포레이티드 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
CN103130735B (zh) 2005-05-10 2016-08-03 因塞特控股公司 吲哚胺2,3-双加氧酶调节剂及其用法
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007075598A2 (en) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP2086979B1 (en) * 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
CA2708361C (en) * 2007-12-14 2016-06-07 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
ES2974437T3 (es) 2008-12-09 2024-06-27 Hoffmann La Roche Anticuerpos ANTI-PD-L1 y su uso para mejorar la función de las células T
ES2788869T3 (es) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anticuerpos anti-GITR
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
EP2510010B1 (en) 2009-12-10 2015-11-25 F.Hoffmann-La Roche Ag Antibodies binding to human CSF1R extracellular domain 4 and their use
CA2791658C (en) 2010-03-04 2019-10-01 Macrogenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX336682B (es) 2010-03-05 2016-01-27 Hoffmann La Roche Anticuerpos contra csf-1r humanos y usos de los mismos.
JP2013521765A (ja) 2010-03-05 2013-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
CN112480256A (zh) 2010-05-04 2021-03-12 戊瑞治疗有限公司 结合csf1r的抗体
JP6105470B2 (ja) 2010-09-09 2017-03-29 ファイザー・インク ４−１ｂｂ結合分子
US8957077B2 (en) * 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
NO2694640T3 (es) 2011-04-15 2018-03-17
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
MX363696B (es) * 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
CA2858069C (en) * 2011-12-08 2020-02-11 Novartis Ag Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
EP2812355A4 (en) 2012-02-06 2016-03-02 Hoffmann La Roche COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
KR20220162819A (ko) 2012-05-11 2022-12-08 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2882804A1 (en) 2012-08-31 2014-03-06 Brian Wong Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9637491B2 (en) * 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
SG11201908624SA (en) 2017-04-12 2019-10-30 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and uses thereof
EP3612030B1 (en) 2017-04-21 2025-12-24 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
AU2019360204A1 (en) 2018-10-16 2021-06-03 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
JP2023503167A (ja) 2019-11-26 2023-01-26 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
US20230039711A1 (en) 2020-01-10 2023-02-09 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
AU2021369590A1 (en) 2020-10-28 2023-06-22 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981911B2 (en) 2016-12-16 2021-04-20 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11059823B2 (en) 2016-12-16 2021-07-13 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11827638B2 (en) 2016-12-16 2023-11-28 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US12202831B2 (en) 2016-12-16 2025-01-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11066406B2 (en) 2018-06-15 2021-07-20 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11787807B2 (en) 2018-06-15 2023-10-17 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases

Also Published As

Publication number Publication date
IL270025B1 (en) 2023-01-01
CO2019011584A2 (es) 2020-02-18
IL270025A (es) 2019-12-31
JP2022116319A (ja) 2022-08-09
US12077542B2 (en) 2024-09-03
MX2019012431A (es) 2020-08-03
EP3612030A2 (en) 2020-02-26
JP7232244B2 (ja) 2023-03-08
BR112019021992A2 (pt) 2020-06-09
KR20190141722A (ko) 2019-12-24
SG11201909710XA (en) 2019-11-28
AU2018256459A1 (en) 2019-11-07
TWI778050B (zh) 2022-09-21
AU2018256459B2 (en) 2023-12-07
TW201841917A (zh) 2018-12-01
US20230028336A1 (en) 2023-01-26
CN110831600B (zh) 2023-10-17
US11358969B2 (en) 2022-06-14
CA3059939A1 (en) 2018-10-25
JP2020517734A (ja) 2020-06-18
CN110831600A (zh) 2020-02-21
IL270025B2 (en) 2023-05-01
EP3612030A4 (en) 2021-04-28
US20180327411A1 (en) 2018-11-15
US10570138B2 (en) 2020-02-25
WO2018195397A3 (en) 2018-12-13
KR102668371B1 (ko) 2024-05-28
EP3612030B1 (en) 2025-12-24
ZA201906822B (en) 2024-06-26
US10689388B1 (en) 2020-06-23
US20200331917A1 (en) 2020-10-22
WO2018195397A2 (en) 2018-10-25
US20250122205A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
EA202190726A1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP17023281A (es) Inhibidores de mk2 y sus usos
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
MA47585A (fr) Composés modulateurs du récepteur des hydrocarbures aryle (ahr)
CL2018000696A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2018000511A (es) Derivados de fenoximetilo.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX384883B (es) Métodos para usar activadores de piruvato cinasa.
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
ECSP16088687A (es) Composiciones novedosas, usos y métodos para hacerlas
ECSP19055179A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.